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Editorial on the Research Topic:
Platelets as Players in Neuropathologies: Novel Diagnostic and Therapeutic Targets
The revised view of platelets, or thrombocytes, from megakaryocytes-derived cell fragments
dedicated to hemostasis, to pivotal elements in inflammation and autoimmunity is now well-
documented (1, 2). Over recent decades, unexpected evidence has highlighted the multifaceted
functions of these unique cells (3–5):
1. Platelets are anucleate cells of 1.5-3 µm in diameter in humans (0.5-1.0 µm in mice), of high
abundance (150-450 x103/µl in humans; 1,000-1,500 x103/µl in mice) and short lifespan (8-9 days
in humans; 4-5 days in mice). However, their estimated 3,700 different proteins, relate not only to
hemostasis, but to defence, cell-cell communication and the inflammatory response (6, 7).
2. Platelets carry rough endoplasmic reticulum, polyribosomes and stable megakaryocyte-derived
mRNA transcripts, selected during thrombopoiesis. Also identified are 284 miRNA species
regulating protein expression via miRNA-mRNA pairings (8, 9).
3. Platelets are high extracellular vesicle (EV) producers. Platelet-derived microvesicles account for
up to 70–90 % of total EV in peripheral blood (10).
4. Platelets exhibit rapid changes of phenotype by acquiring unique mRNA and protein profiles,
depending on pathological status (11).
Consequently, platelets instantaneously sense danger signals and respond by recruitment of
innate immune cells, triggering an adaptive immune response. In this context, we organized a
Research Topic in Frontiers in Immunology with a focus on two themes: (1) similarities between
platelets and neurons in expression profile and (2) their potential as biomarkers and therapeutic
targets. We gathered five original papers and four reviews on the role of platelets in
neuroinflammatory diseases, such as multiple sclerosis (MS) and neurodegenerative/
neuropsychiatric disorders, particularly stroke, Alzheimer disease (AD) and Parkinson’s
disease (PD).
The review by Leiter and Walker provides an updated overview of current evidence on platelet
function and details how platelets are pivotal to immune responses, tissue remodeling and healthy
brain function. Significantly, platelets express multiple components regarded as bona fide neuronal
proteins, including neurotransmitters for central nervous system intercellular communication,org September 2021 | Volume 12 | Article 7723521
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neuronal plasticity and Alzheimer’s precursor protein (APP)
and its metabolite beta-amyloid (Aß). Additionally, there are
shared mechanisms between platelets and neurons in
neurotransmitter storage and release, secretory pathways and
uptake and packaging (Leiter and Walker) (12). Therefore,
plate let hyperact ivat ion has major implicat ions in
neurodegenerative conditions.
Consequently, the identification of release markers of platelet
activation is a major pursuit. Inyushin and colleagues explore the
role of systemic platelet-derived APP and Aß peptides,
particularly the Aß1-40 peptide predominant in platelets (as
opposed to Aß1-42 predominant in brain), in various forms of
amyloidosis (Inyushin et al.). Platelet-derived Aß has immune
functions in infection, where APP processing is non-
amyloidogenic. However, this changes in amyloidosis
disorders, when systemic Aß contributes to vascular damage.
The consensus is that the platelet shift in APP processing to Aß
represents an excellent model to study blood-based AD
biomarkers. In contrast, evidence also suggests a complex
picture whereby changes in platelet components are
incompletely replicated in plasma. This is the case for brain-
derived neurotrophic factor (BDNF) and its precursor proBDNF,
where the cerebrospinal fluid proBDNF/BDNF ratio is a
candidate AD biomarker. Plasma and platelets also contain
proBDNF and BDNF, but studies from the Lordkipanidze
group (Le Blanc et al.; Fleury et al.) show that unlike BDNF,
proBDNF is not released from platelets upon activation showing
a different proBDNF/BDNF regulation between CNS
and plasma.
With similar objectives in mind, Humpel’s group (Foidl et al.)
used a lipidomic approach to profile the lipid expression pattern
in a murine model of sporadic cerebral amyloid angiopathy
(CAA), a vascular pathology which occurs independently, or as a
frequent AD co-morbidity. CAA diagnosis relies on vascular
deposition of Aß1-40. Alterations in lipid profiles in both platelets
and plasma (6 platelet lipids and 15 plasma lipids) were
identified in the CAA model, which does not exhibit AD
pathology, but with differential signatures. Given the difficulty
of diagnosing pure CAA, the identification of a unique lipid
profile in this disorder may lead to earlier differentiation between
CAA and AD.
The potential of classical platelet parameters such as mean
platelet volume, platelet count and platelet distribution width as
early disease markers is also being explored. Gialluisi’s group
(Tirozzi et al.) identified a significant genetic correlation between
platelet distribution width and PD risk, but not between AD and
platelet parameters. Given that platelet distribution width is an
index of platelet procoagulant activity, this parameter may
represent a risk indicator for certain neurodegenerative/
neuropsychiatric disorders.
The Langer group describes the interplay between platelets
and the complement system as well as plasmatic coagulation
factors and the potential clinical benefit of targeting platelet-
mediated neuroinflammation as an adjunct therapy to mitigate
disease severity in MS and stroke-associated brain injury (RawishFrontiers in Immunology | www.frontiersin.org 2et al.). Such developments prompted the design of an MS study
by Koudriavtseva and colleagues seeking to establish a link
between the pathogenet ic role of coagulat ion and
hemodynamic abnormalities in MS. This study aims to
correlate magnetic resonance imaging-identified brain
hemodynamic changes with altered coagulation/complement
factor profiles and related damage markers, with the long-term
goal of validating the coagulation system as a therapeutic target
in MS (Koudriavtseva et al.).
Concurrently, as described by Orian and collaborators,
avenues for platelet imaging and targeting are being explored.
The platelet-specific GPIIb/IIIa receptor undergoes
conformational changes during activation, thereby exposing a
ligand binding pocket enabling differential targeting of the
activated counterpart, but not resting platelets. Since activated
platelets accumulate at the site of injury, platelet imaging when
combined with other imaging approaches may provide improved
sensitivity for longitudinal monitoring and candidate therapeutic
evaluation. The concept of platelet targeting for therapeutic ends
has been hampered by the risk of bleeding complications, but
refined targeting of activation-specific epitopes warrants
further investigation.
While the link between platelets and neuropathologies is
strengthening, similar revelations are being made in other fields.
Studies have highlighted the cross-talk between platelets and
cancer cells and the role of platelets in tumor metastasis (13,
14). Work in cerebral malaria has shown that both platelets and
platelet-derived EV contribute to pathology (15). Therefore,
advances in determining the potential of platelets in diagnosis,
patient monitoring and as therapeutic targets, would benefit from
improved understanding of shared mechanisms across conditions
where platelets drive pathological progression and of platelet
interaction with their target organs over disease evolution.AUTHOR CONTRIBUTIONS
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